Defendant

Medacta USA, Inc.

1 case as defendant.

Cases
1
Active
1
0 closed
Filed
2019
Top venue
D Del
1 case

Company profile

Medacta USA, Inc. is the U.S. subsidiary of Medacta Group SA (SIX: MOVE), a Swiss orthopedic device maker founded in 1999 and headquartered in Castel San Pietro, Switzerland. Medacta USA is a Delaware corporation that serves the North American market. Its U.S. headquarters has moved several times — Camarillo, CA; Chicago; Memphis; Franklin, TN (2019) — and Medacta announced in 2026 that it will relocate U.S. headquarters and build a U.S. manufacturing hub in Spring Hill, TN. The parent group reported FY2024 revenue of €590.6 million (FY2025: ~€684 million) with about 1,900–2,000 employees, and is publicly listed with a market capitalization in the low billions of Swiss francs.

Operations. Medacta designs, manufactures and distributes joint-replacement and spine surgery products, organized into hip, knee, extremities (shoulder and sports medicine) and spine lines. Hip products center on the AMIS anterior minimally invasive surgery platform; knee offerings include the GMK Sphere and GMK SpheriKA implants, the MyKA kinematic-alignment platform and MyKnee patient-specific cutting guides; extremities include the MyShoulder patient-specific guides and NextAR augmented-reality shoulder application; spine includes NextAR Spine. The company also runs the M.O.R.E. Institute surgeon-education program. This is a genuine operating business, not a shell licensor.

Litigation posture. Medacta USA appears in the tracked data only as a defendant (0 plaintiff, 1 defendant case), consistent with an operating company being sued rather than an active patent enforcer. The single tracked matter was filed in the District of Delaware, not a plaintiff-friendly Texas venue.

Notable case. Conformis, Inc. v. Medacta USA, Inc. et al. (D. Del., filed Aug. 29, 2019) accused Medacta's MyKnee patient-specific instrumentation of infringing several Conformis patents (U.S. 8,377,129; 8,460,304; 9,186,161; 9,295,482). The case was consolidated with Conformis's parallel Zimmer Biomet action. In November 2022, Medacta and Conformis settled all patent disputes: Medacta received a non-exclusive license to certain Conformis patient-specific instrumentation patents, paying a low single-digit million-dollar sum.

Conformis, Inc. v. Medacta USA, Inc. et al.

pending
Docket:
1:19-cv-01618
Court:
D. Del.
Filed:
2019-08-29
Patents:8556983

Conformis sued Medacta USA and Medacta International in the District of Delaware. Amended complaints were filed in December 2019 and October 2020; later service-of-process and personal-jurisdiction rulings occurred in 2022. Narrative states the '983 patent was not identified as asserted in this case.